Live Breaking News & Updates on Esperion Therapeutics Inc|Page 5

Stay updated with breaking news from Esperion therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from Needham & Company LLC

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from Needham & Company LLC
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Simplicity Wealth , Esperion Therapeutics Inc , Mesirow Financial Investment Management Inc , Boomfish Wealth Group , Needham Company , Sg Americas Securities , Esperion Therapeutics Company Profile , Summit Financial , Esperion Therapeutics , Get Free Report , Wealth Group , Financial Investment Management , Esperion Therapeutics Daily ,

Esperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLC

Esperion Therapeutics' (ESPR) Buy Rating Reaffirmed at Needham & Company LLC
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Esperion Therapeutics Inc , Armistice Capital , Needham Company , Connor Clark Lunn Investment Management Ltd , Capital Partners , Esperion Therapeutics , Get Free Report , Asset Management , Connor Clark , Lunn Investment Management , Esperion Therapeutics Daily ,

Q4 2025 Earnings Forecast for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Issued By Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Zacks Research cut their Q4 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will earn $0.14 per share for the quarter, […] ....

United States , Esperion Therapeutics Inc , Simplicity Solutions , Connor Clark Lunn Investment Management Ltd , Esperion Therapeutics Company Profile , Zacks Research , Capital Partners , Needham Company , Pinnacle Associates Ltd , Esperion Therapeutics , Free Report , Esperion Therapeutic , Get Free Report , Lunn Investment Management , Pinnacle Associates , Esperion Therapeutics Daily , Nasdaq Espr , Earnings Estimates ,

Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target at $9.33

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has received a consensus recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among […] ....

United States , Needham Company , Esperion Therapeutics Company Profile , Capital Partners , Connor Clark Lunn Investment Management Ltd , Esperion Therapeutics Inc , Armistice Capital , Esperion Therapeutics , Get Free Report , Marketbeat Ratings , Therapeutics Stock Down , Asset Management , Connor Clark , Lunn Investment Management , Get Free , Esperion Therapeutics Daily , Nasdaq Espr ,